Abstract

Abstract Tumor relapse after chemotherapy typifies hepatocellular carcinoma (HCC) and is believed to be attributable to residual cancer stem cells (CSCs) that survive initial treatment. Chronic infection with hepatitis B virus (HBV) has long been linked to the development of HCC. Upon chronic infection, random HBV genome integration can lead to truncation of hepatitis B virus X (HBx) protein at the C-terminus. The resulting C-terminal-truncated HBx (HBx-ΔC) was previously shown to confer enhanced invasiveness and diminished apoptotic response in HCC cells. In this study, we found HBx-ΔC to be more frequently detected in HCC clinical samples than their matched non-tumor counterparts. In addition, we also identified a strong positive correlation between HBx-ΔC and the liver cancer stem cell marker CD133, in a panel of liver cell line tested. Subsequently, we delineated the role of a naturally occurring HBx-ΔC (HBx-Δ14) in promoting stemness and aggressive behaviors in HCC cells. The stable overexpression of HBx-Δ14 in HCC cell line (Huh7) and immortalized normal liver cell line (MIHA) promoted expression of stemness markers, EpCAM and SOX2. In vitro functional studies with HBx-Δ14 stably overexpressed in Huh7 demonstrated an increased ability to self-renew, resist chemotherapy (5-fluorouracil) and targeted therapy (sorafenib), migrate and induce capillary tube formation in endothelial cells. Similar functional results were also obtained when HBx-Δ14 was stably overexpressed in MIHA cells. Taken together, in addition to its role in enhancing HCC metastasis, we find HBx-Δ14 to confer cancer and stem cell-like features in HCC, and to play an important role in driving tumor relapse in this deadly disease. Citation Format: Kai Yu Ng, Stella Chai, Man Tong, Xin-Yuan Guan, Alfred S. Cheng, Stephanie Ma. C-terminal truncated hepatitis B virus X protein promotes hepatocarcinogenesis through enhanced stemness and resistance to therapy. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2223. doi:10.1158/1538-7445.AM2015-2223

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call